{"drugs":["Grastek","Timothy Grass Pollen Allergen Extract"],"mono":{"0":{"id":"930944-s-0","title":"Generic Names","mono":"Timothy Grass Pollen Allergen Extract"},"1":{"id":"930944-s-1","title":"Dosing and Indications","sub":[{"id":"930944-s-1-4","title":"Adult Dosing","mono":"<ul><li>administer first dose in a healthcare setting under supervision of a physician experienced with severe allergic reactions; monitor patient closely for 30 minutes<\/li><li><b>missed dose:<\/b> limited data available regarding safety of restarting treatment after a missed dose<\/li><li><b>Allergic rhinitis due to grass pollens - Grass desensitization therapy:<\/b> 1 tablet (2800 bioequivalent index of reactivity) SL once daily, started 3 months prior and continued through grass pollen season<\/li><\/ul>"},{"id":"930944-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>administer first dose in a healthcare setting under supervision of a physician experienced with severe allergic reactions; monitor patient closely for 30 minutes<\/li><li><b>missed dose:<\/b> limited data available regarding safety of restarting treatment after a missed dose<\/li><li><b>Allergic rhinitis due to grass pollens - Grass desensitization therapy:<\/b> (5 to 17 years) 1 tablet (2800 bioequivalent index of reactivity) SL once daily, started 3 months prior and continued through grass pollen season<\/li><\/ul>"},{"id":"930944-s-1-6","title":"Dose Adjustments","mono":"<b>Geriatric:<\/b> safety and efficacy not evaluated in patients older than 65 years "},{"id":"930944-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Allergic rhinitis due to grass pollens - Grass desensitization therapy<br\/>"}]},"2":{"id":"930944-s-2","title":"Black Box Warning","mono":"<b>Sublingual (Tablet)<\/b><br\/>Timothy Grass Pollen Allergen Extract can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. Do not administer Timothy Grass Pollen Allergen Extract to patients with severe, unstable or uncontrolled asthma, and observe patients in the office for at least 30 minutes following the initial dose. Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. Timothy Grass Pollen Allergen Extract may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction, or in patients who may be unresponsive to epinephrine or inhaled bronchodilators (eg, those taking beta-blockers).<br\/>"},"3":{"id":"930944-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930944-s-3-9","title":"Contraindications","mono":"<ul><li>asthma, severe, unstable or uncontrolled<\/li><li>eosinophilic esophagitis, history of<\/li><li>hypersensitivity to any inactive ingredient (eg, gelatin, mannitol and sodium hydroxide)<\/li><li>local reaction to sublingual allergen immunotherapy, severe, history of<\/li><li>systemic allergic reaction, severe, history of<\/li><\/ul>"},{"id":"930944-s-3-10","title":"Precautions","mono":"<ul><li>local reactions, severe, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening, may occur; consider discontinuation for escalating or persistent local reactions in the mouth or throat<\/li><li>systemic allergic reactions, life-threatening, such as anaphylaxis may occur; administer initial dose in a healthcare setting and observe patient for at least 30 minutes after dose; prescribe auto-injectable epinephrine for emergent use; discontinue after allergic reaction<\/li><li>acute asthma exacerbation; withhold therapy during exacerbation; reevaluate patient with recurrent asthma exacerbation and consider discontinuation<\/li><li>compromised lung function (chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, or uncontrolled hypertension; may reduce ability to survive a serious allergic reaction or increase risk of adverse reactions with epinephrine administration<\/li><li>concomitant allergen immunotherapy; may increase likelihood of local or systemic adverse reactions to either subQ or SL allergen immunotherapy<\/li><li>concomitant beta-adrenergic blockers; may be unresponsive to usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis<\/li><li>eosinophilic esophagitis has been reported with SL tablet immunotherapy; discontinue in presence of severe or persistent gastroesophageal symptoms, including dysphagia or chest pain<\/li><li>oral inflammation (eg, oral lichen planus, mouth ulcers, or thrush) or wounds (eg, after oral surgery or dental extraction); stop therapy to allow complete healing<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930944-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"930944-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930944-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Edema of oral soft tissues (adult, 11.1%; pediatric, 9.8%), Itching, Oral (adult, 26.7%; pediatric, 24.4%), Itching, Tongue (adult, 5.7%; pediatric, 9.2%), Oral paresthesia (adult, 9.8%; pediatric, 5.4%), Throat irritation (adult, 22.6%; pediatric, 21.3%)<\/li><li><b>Otic:<\/b>Ear problem, Pruritus (adult, 12.5%; pediatric, 7.2%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Eosinophilic esophagitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Airways obstruction reversible, Asthma, Swelling, Laryngopharyngeal<\/li><\/ul>"},"6":{"id":"930944-s-6","title":"Drug Name Info","sub":{"0":{"id":"930944-s-6-17","title":"US Trade Names","mono":"Grastek<br\/>"},"2":{"id":"930944-s-6-19","title":"Class","mono":"Immunological Agent<br\/>"},"3":{"id":"930944-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930944-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930944-s-7","title":"Mechanism Of Action","mono":"The exact mechanism of allergen immunotherapy is unknown.<br\/>"},"9":{"id":"930944-s-9","title":"Administration","mono":"<b>Sublingual<\/b><br\/><ul><li>SL administration only<\/li><li>administer first dose under supervision of a physician with experience in diagnosis and treatment of severe allergic reactions; observe patient for at least 30 minutes<\/li><li>remove from blister pack just prior to dosing; place tablet under tongue for at least 1 minute (until complete dissolution) and then swallow<\/li><li>wash hands after handling tablet; avoid food or beverages for 5 minutes after administration<\/li><\/ul>"},"10":{"id":"930944-s-10","title":"Monitoring","mono":"<ul><li>improvement in symptoms of allergic rhinitis or decreased use of rescue medication indicate efficacy<\/li><li>signs or symptoms of severe allergic reaction; observe for at least 30 minutes after initial dose<\/li><li>escalating or persistent local reactions in mouth and throat; consider discontinuation of treatment<\/li><li>recurrent asthma exacerbations; reevaluate and consider discontinuation of treatment<\/li><\/ul>"},"11":{"id":"930944-s-11","title":"How Supplied","mono":"<b>Grastek<\/b><br\/>Sublingual Tablet: 2800 BAU<br\/>"},"13":{"id":"930944-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient about the symptoms of a severe allergic reaction and the proper use of emergency self-injection epinephrine.<\/li><li>Instruct patient to immediately report use of emergency self-injection epinephrine.<\/li><li>Advise asthma patient to immediately report difficulty breathing or worsening of asthma symptoms.<\/li><li>Side effects may include throat irritation, mouth edema, or pruritus of ears, mouth, or tongue.<\/li><li>Warn patient to report severe or persistent symptoms of esophagitis, including dysphagia or chest pain.<\/li><li>Instruct patient to place tablet under tongue and do not swallow until completely dissolved (at least one minute).<\/li><li>Advise patient to avoid taking drug with food or beverage. Do not consume food or beverage for at least 5 minutes after dissolution.<\/li><li>Tell patient to wash hands immediately following administration.<\/li><li>Counsel patient to skip a missed dose and resume normal schedule the next day. If more than one dose is missed, patient should contact physician.<\/li><\/ul>"}}}